• Notice of Correction to PA-15-087 "Development of Novel and Emerging Technologies to Support Zebrafish Models for Biomedical Research (R41/R42)"
  (NOT-OD-15-074) Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
• Notice of Correction to PA-15-086 "Development of Novel and Emerging Technologies to Support Zebrafish Models for Biomedical Research (R43/R44)"
  (NOT-OD-15-075) Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
• Eye on NIH Policy: OMB Uniform Guidance - What it Means for NIH & You (Video & Interactive Q&A - March 12, 2015)
  (NOT-OD-15-077) National Institutes of Health
• NCCIH Policy for Submission of R21 Applications Containing Clinical Trials
  (NOT-AT-15-004) National Center for Complementary and Integrative Health
• Notice of Clarification of Application Instructions in PAR-14-240 "Collaborative Research Projects to Enhance Applicability of Mouse Models for Translational Research (Collaborative R01)"
  (NOT-CA-15-016) National Cancer Institute
• Notice of Clarification for RFA-DA-15-014 Adolescent Brain Cognitive Development (ABCD) Study - Coordinating Center (U24)
  (NOT-DA-15-051) National Institute on Drug Abuse
National Cancer Institute
National Institute on Alcohol Abuse and Alcoholism
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Mental Health
National Institute on Minority Health and Health Disparities
Office of Behavioral and Social Science Research
• AHRQ Announces Continued Interest in Career Development and Dissertation Awards
  (NOT-HS-15-007) Agency for Healthcare Research and Quality
• Notice of Change to the Eligible Activity Codes for PA-15-122 "Administrative Supplements for Common Basic Sociobehavioral Mechanisms and Processes that Facilitate or Impede Self-Management of Chronic Conditions (Admin Supp)"
  (NOT-OD-15-076) Office of Behavioral and Social Science Research
• Use of Updated Inclusion Enrollment Format Now Required for Successful Submission of RPPR
  (NOT-OD-15-078) National Institutes of Health
• Request for Information (RFI): Availability of Data and Biological Specimens from NIH-funded Studies of HIV and Non-HIV-Infected Injection Drug Users for Genetic and Epigenetic Analyses
  (NOT-DA-15-052) National Institute on Drug Abuse
• Notice of NIDDK Participation in RFA-CA-15-006 "Big Data to Knowledge (BD2K) Advancing Biomedical Science Using Crowdsourcing and Interactive Digital Media (UH2)"
  (NOT-DK-15-007) National Institute of Diabetes and Digestive and Kidney Diseases
• Notice of NIEHS' Participation in RFA-CA-15-006 "NIH Big Data to Knowledge (BD2K) Advancing Biomedical Science Using Crowdsourcing and Interactive Digital Media (UH2)"
  (NOT-ES-15-013) National Institute of Environmental Health Sciences
  (NOT-ES-15-016) National Institute of Environmental Health Sciences
• Notice of NIGMS's Participation in PAR-15-048 "Systems Science and Health in the Behavioral and Social Sciences (R01)"
  (NOT-GM-15-101) National Institute of General Medical Sciences
• Request for Information (RFI): Invitation to Comment on Effectiveness of an Earlier Request for Proposals (RFP) for A Repository of Mouse Models for Cytogenetic Disorders
  (NOT-HD-15-003) Eunice Kennedy Shriver National Institute of Child Health and Human Development
Notice of National Heart, Lung, and Blood Institute (NHLBI) Participation in PA-15-027 "Research on Eosinophil Associated Disorders (R01)"
(NOT-HL-15-254)
National Heart, Lung, and Blood Institute

Notice of Correction to PA-15-100 "Maternal Nutrition and Pre-pregnancy Obesity: Effects on Mothers, Infants and Children (R01)"
(NOT-NR-15-002)
National Institute of Nursing Research

Notice of National Center for Advancing Translational Sciences (NCATS) Participation in RFA-CA-15-006 "Big Data to Knowledge (BD2K) Advancing Biomedical Science Using Crowdsourcing and Interactive Digital Media (UH2)"
(NOT-TR-15-010)
National Center for Advancing Translational Sciences

REQUESTS FOR APPLICATIONS

**TITLE:** Mobilizing Research: A Research Resource to Enhance mHealth Research (U2C)
(RFA-OD-15-129)
**SPONSOR:** Office of Behavioral and Social Science Research, National Heart, Lung, and Blood Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute of Biomedical Imaging and Bioengineering, National Institute of Neurological Disorders and Stroke

**TITLE:** SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics and Prognostics Toward Commercialization (R44)
(RFA-CA-15-010)
**SPONSOR:** National Cancer Institute.

**Synopsis:** This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. Projects proposed in response to this FOA must be applicable to one of the following areas: (1) cancer therapeutics; (2) cancer imaging technologies, interventional devices, and in vivo diagnostics; or (3) in vitro and ex vivo cancer diagnostics and prognostics. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all Phase II SBIR applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required

Application Receipt/Submission Date(s): LOI due April 13, 2015; Full Applications due May 13, 2015.

**TITLE:** Summer Institute for Research Education in Biostatistics (R25)
(RFA-HL-16-017)
**SPONSOR:** National Heart, Lung, and Blood Institute

**TITLE:** Biological and Physiological Effects of E-cigarette Aerosol Mixtures (R01)
(RFA-DE-16-004)
National Institute of Dental and Craniofacial Research, Office of Disease Prevention Application Receipt Date(s): July 28, 2015

**TITLE:** Biological and Physiological Effects of E-cigarette Aerosol Mixtures (R21)
(RFA-DE-16-005)
National Institute of Dental and Craniofacial Research, Office of Disease Prevention Application Receipt Date(s): July 28, 2015

PROGRAM ANNOUNCEMENTS

**TITLE:** Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01)
(PA-15-135)
**SPONSOR:** National Institute of Dental and Craniofacial Research, National Center for Complementary and Integrative Health, National Cancer Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse,
National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of General Medical Sciences, Office of Dietary Supplements

**Synopsis:** The purpose of this funding opportunity announcement (FOA) is twofold: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other "-omic" sciences, biotechnology, and bioinformatics. - See more at: http://grants.nih.gov/grants/guide/pa-files/PA-15-135.html#sthash.Ak8PjbJ4.dpuf

Application Receipt/Submission Date(s): Multiple dates; see announcement for details.

**TITLE:** Availability of Administrative Supplements to NIGMS Predoctoral Training Grants (Admin Supp) (PA-15-136)

**SPONSOR:** National Institute of General Medical Sciences

Application Receipt/Submission Date(s): Multiple dates, see announcement.

**TITLE:** NIDDK Research Education Program Grants for Curriculum Development (R25) (PAR-15-138)

**SPONSOR:** National Institute of Diabetes and Digestive and Kidney Diseases

Application Receipt/Submission Date(s): Multiple dates, see announcement.

**TITLE:** NIDDK Research Education Program Grants for Courses for Skills Development (R25) (PAR-15-139)

**SPONSOR:** National Institute of Diabetes and Digestive and Kidney Diseases

Application Receipt/Submission Date(s): Multiple dates, see announcement.

**TITLE:** NIDDK Research Education Program Grants for Summer Research Experiences (R25) (PAR-15-140)

**SPONSOR:** National Institute of Diabetes and Digestive and Kidney Diseases

Application Receipt/Submission Date(s): Multiple dates, see announcement.

**OTHER FUNDING OPPORTUNITIES**

**TITLE:** Breast Cancer Research Program (BCRP) – Innovator Award http://www.grants.gov/web/grants/view-opportunity.html?oppId=274906

**SPONSOR:** United States Department of Defense (DoD)

**Synopsis:** The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. The PI should have a past record of challenging the status quo, shifting paradigms by changing a field of research or approach to patient care, exhibiting high levels of creativity, and demonstrating promise for continued innovation in future work. These rare individuals will be able to articulate a vision for ending breast cancer that challenges current dogma and demonstrates an ability to look beyond tradition and convention. The PI is also expected to be established in his/her field and have demonstrated success at forming and leading effective partnerships and collaborations. To further the development of innovative individuals and spark the generation of novel ideas, applications are required to incorporate the mentoring of promising junior investigators. Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research. The PI's research team must include two or more breast cancer consumer advocates. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer and are actively involved in a breast cancer advocacy organization. Their role should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, breast cancer.

Application Receipt/Submission Date(s): July 26th, 2015.

**TITLE:** Breast Cancer Research Program (BCRP) – Breakthrough Award – Level 3 and 4 http://www.grants.gov/web/grants/view-opportunity.html?oppId=274904

**SPONSOR:** United States Department of Defense (DoD)

**Synopsis:** The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. Two different funding levels, based on the scope of the research, are available under this Program Announcement. It is the responsibility of the Principal Investigator (PI) to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget. The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level: • Funding Level 3: Advanced translational studies that have potential for near-term clinical investigation. Small-scale clinical
trials may apply. • Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Near-term clinical impact is expected. PIs are expected to have experience in successfully leading large-scale projects. Note: An invited oral presentation is a requirement for application review of Funding Level 4 projects, as described in Section II.C., Application Submission Content and Forms. Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive collaborations between investigators.

Application Receipt/Submission Date(s): July 28th, 2015.

- **TITLE:** Breast Cancer Research Program (BCRP) – Distinguished Investigator Award  

  **SPONSOR:** United States Department of Defense (DoD)

  **Synopsis:** The BCRP Distinguished Investigator Award enables established visionary leaders from any field to pursue innovative ideas that could accelerate progress toward ending breast cancer. These individuals should be exceptionally talented researchers who have shown that they are leaders in their field(s) through extraordinary creativity, vision, and productivity. The central feature of the Distinguished Investigator Award is that the PI must propose research that is a fundamental shift from his/her track record of research and addresses one or more BCRP overarching challenge(s). Proposals that are a continuation or incremental change from the PI’s published line of research do not meet the intent of this award. High-risk/high-reward proposals with limited preliminary data are welcomed, but not required. All applications must include a well-formulated, testable hypothesis based on strong scientific rationale. Experience in breast cancer research is not required; however, the application must focus on breast cancer. Individuals from other disciplines who will apply novel concepts to breast cancer are encouraged to submit. The PI is expected to assemble a research team that will provide the necessary expertise and collaborative efforts toward accomplishing the research goals. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer and are actively involved in a breast cancer advocacy organization.

  Application Receipt/Submission Date(s): July 28th, 2015.

- **TITLE:** Breast Cancer Research Program (BCRP) – Breakthrough Award – Levels 1 and 2  

  **SPONSOR:** United States Department of Defense (DoD)

  **Synopsis:** The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The funding level should be selected based on the scope of the research project, rather than the amount of the budget. The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level: • Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development. Research with potential to yield new avenues of investigation. Proof of concept. No preliminary data required. • Funding Level 2: Research that is already supported by preliminary data and has potential to make significant advancements toward clinical translation. Demonstration of efficacy in in vivo models, as applicable. Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive collaborations between investigators. Applications submitted by a mentor and his/her current postdoctoral fellow or junior investigator as Initiating and Partnering PIs do not meet the intent of the Partnering PI Option.

  Application Receipt/Submission Date(s): Pre Application due April 8, 2015; Full Application due April 22nd, 2015.

- **TITLE:** Breast Cancer Research Program (BCRP) – Era of Hope Scholar Award  

  **SPONSOR:** United States Department of Defense (DoD)

  **Synopsis:** Since the intent of the Era of Hope Scholar Award is to recognize creative and innovative individuals rather than projects, the central feature of the award are the applicant’s demonstrated ability to go beyond conventional thinking in their field and the innovative contribution that the Principal Investigator (PI) can make toward ending breast cancer. The PI should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention. Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research. The PI is expected to assemble a research team that will provide the necessary expertise and collaborative efforts toward accomplishing the research goals. The PI’s research team must include two or more breast cancer consumer advocates.

  Application Receipt/Submission Date(s): April 22nd, 2015.

- **TITLE:** Paul Marks Prize for Cancer Research  

  **SPONSOR:** Memorial Sloan Kettering Cancer Center (MSKCC)

  **Synopsis:** The Paul Marks Prize for Cancer Research recognizes a new generation of leaders in cancer research, who are making significant contributions to the understanding of cancer or are improving the treatment of the disease through basic or clinical research. The prize is intended to encourage young investigators who have a unique opportunity to help shape the future of cancer research.

  Application Receipt/Submission Date(s): April 30th, 2015.
• TITLE: AACR Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen
  
  http://www.aacr.org/Research/Awards/Pages/Awards-Detail.aspx?ItemId=15#
  
  SPONSOR: American Association for Cancer Research
  
  Synopsis: The AACR Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen®, recognizes an investigator of no more than 50 years of age whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of breast cancer. Such work may involve any discipline across the continuum of biomedical research, including basic, translational, clinical and epidemiological studies.
  
  Application Receipt/Submission Date(s): April 15th, 2015.

• TITLE: SU2C-Cancer Research UK-Lustgarten Foundation Pancreatic Cancer Dream Team Translational Research Grant
  
  http://www.aacr.org/Funding/Pages/Funding-Detail.aspx?ItemID=47#.VQhpKI5zS_0
  
  SPONSOR: American Association for Cancer Research
  
  Synopsis: The grants provides four years of research fellowship support to the most talented and promising early-career investigators in the United States and the United Kingdom who have completed their Ph.D. or clinical training and demonstrate clear potential to become leaders in their fields. Research projects must be translational in nature and address critical problems in cancers with the potential to deliver patient benefit. Up to four fellows will be funded by this grant opportunity.
  
  Application Receipt/Submission Date(s): LOI due 6/2015; Full Applications due 8/24/2015

• TITLE: Bridge Funding Program
  
  http://www.marsharivkin.org/research/apply.html
  
  SPONSOR: Marsha Rivkin Center for Ovarian Cancer Research

• TITLE: Bio-Therapeutics Impact Awards
  
  http://www.alexslemonade.org/grants/guidelines
  
  SPONSOR: Alex’s Lemonade Stand Foundation for Childhood Cancer

• TITLE: Medical Research Grants: Reach Awards
  
  http://www.alexslemonade.org/grants/guidelines
  
  SPONSOR: Alex’s Lemonade Stand Foundation for Childhood Cancer

• TITLE: “A” Award
  
  http://www.alexslemonade.org/grants/guidelines
  
  SPONSOR: Alex’s Lemonade Stand Foundation for Childhood Cancer